

CELL & GENE THERAPY REVOLUTION

Get ready!

in partnership
with



BioCanRx
Biotherapeutics for Cancer Treatment
Biothérapies pour le traitement du cancer



Center for
Commercialisation of
Cancer
IMMUNOTHERAPY

CellCAN's First
Pancanadian Strategic Forum
on Cell & Gene Therapy

From Discovery to Commercialization

March 9 & 10, 2017
Montreal, Canada

KNOWLEDGE – MOBILIZATION – ACTIONS
WWW.CELLCAN.COM/FORUM2017



NCE RCE

Supported by the Government of Canada through
the Networks of Centres of Excellence – KM programs.

SPECIAL ACKNOWLEDGEMENTS

SCIENTIFIC COMMITTEE:

- François Bettez, Chief Executive Officer, C3i
- Catherine Bollard, President, International Society for Cell Therapy
- Lambert Busque, Chief Medical Officer, C3i
- Adrian Gee, Director, Clinical Applications Lab, Baylor College of medicine
- Armand Keating, Director, Cell Therapy Program, University Health Network
- Stephanie Michaud, President and Chief Executive Officer, BioCanRx
- Denis Claude Roy, Chief Executive Officer, CellCAN

ORGANIZING COMMITTEE:

- Véronique Arsenault, Consultant in Communications and Event Management, Exponentiel Conseil
- Marie-Eve Desormeaux, Project Manager, CellCAN
- Vanessa Laflamme, Chief Operating Officer, CellCAN
- Florence Meney, Consultant in Media Relations
- Erin Hillhouse, Translator

EVENT COORDINATION TEAM:

- | | |
|---|---|
| Creatures
Branding and artistic production
www.creatures.ca | Onyris
Web solutions
www.onyris.com |
| Happening.ca
Technical and logistical direction
www.happening.ca | Westin
Facilities, hospitality and banquet services
www.starwoodhotels.com |

THANK YOU FOR MAKING
THIS EVENT A SUCCESS!

WELCOME WORD FROM CELLCAN



Dear attendees,

Thank you for participating in this First PanCanadian Strategic Forum: Cell & Gene Therapy Revolution. For 3 years now, CellCAN’s mission has been to mobilize knowledge and bring stakeholders together in order to advance regenerative medicine in Canada. This strategic forum appropriately reflects our mission, and this first edition is most timely. Indeed, the recent investments in high quality infrastructure relevant to cell manufacturing, the growth of the biotechnology and pharmaceutical fields yielding major developments in regenerative medicine, as well as the high quality fundamental and clinical research conducted in Canada collectively underline the unprecedented expansion of the sector. The recent request by the federal ministries of health, innovation and science to identify the opportunities and challenges associated with regenerative medicine reinforces the immediate need to set clear and strategic directions. This revolution can only be a success by pooling the efforts of all stakeholders and by envisioning the whole continuum, from research to commercialisation. This forum is intended to be a comprehensive overview of this continuum. We hope that this meeting is not an end in itself, but rather the beginning of a collective and concerted movement that will ultimately improve the survival and quality of life of patients and increase the economic impact of this booming sector. Enjoy the forum!

Sincerely,

Denis Claude Roy, M.D.
CEO

Pierre Duplessis, M.D.
Chair of the Board

Chers délégués,

Merci de participer à ce premier forum stratégique pancanadien : Révolution sur les thérapies cellulaires et géniques. Depuis trois ans maintenant, CellCAN a pour mission de mobiliser les connaissances et de réunir les parties prenantes afin de faire avancer la médecine régénératrice au Canada. Ce forum stratégique s’inscrit particulièrement bien dans notre mission, et cette première édition arrive à point. En effet, les investissements des dernières années dans les infrastructures de haut calibre permettant la production cellulaire, la croissance du domaine pharmaceutique et des biotechnologies développant leur expertise en médecine régénératrice, ainsi que l’excellence de la recherche fondamentale et clinique effectuée au Canada démontrent l’engouement du secteur. La demande récente des ministères fédéraux de la santé, de l’innovation et des sciences d’identifier les opportunités et les défis en médecine régénératrice renforce la nécessité d’avoir des orientations stratégiques claires dès maintenant. Mais cette révolution ne peut être une réussite que par la mise en commun des efforts de toutes les parties prenantes et par une vision de l’ensemble du continuum, de la recherche à la commercialisation. Ce forum se veut un survol complet de ce continuum. Nous souhaitons que cette rencontre ne soit pas une fin en soi, mais bien le début d’un mouvement collectif concerté qui permettra ultimement d’améliorer la survie et la qualité de vie des patients ainsi que d’accroître les impacts économiques de ce secteur en pleine explosion. Bon forum à tous !

Sincèrement,

Denis Claude Roy, M.D.
Directeur général

Pierre Duplessis, M.D.
Président du conseil d’administration

OUR MISSION


Mobilize stakeholders and knowledge across Canada to significantly advance regenerative medicine and cell therapy research and clinical development.

OUR GOAL

Improve Canadians’ health by accelerating and facilitating the development of stem cell therapy.

CellCAN allows unprecedented collaboration between all key stakeholders in the field of cell-based therapy. CellCAN is a network of Canada’s main cell therapy centres, whose research teams are working tirelessly to improve our health.

SEVEN FOUNDING NETWORK AFFILIATES



CellCAN’s community is at the forefront of the latest advances in the field.

WE CAN HELP YOU

- Put your knowledge into action;
- Access a network of world class experts;
- Gain access to a datawarehouse of cell manufacturing best practices;
- Organize and co-sponsor events;
- Develop unique training opportunities;
- Produce dissemination tools;
- Advertise your activities.

FUNDED BY



BioCanRx is proud to partner with CellCAN and the Centre for Commercialisation of Cancer Immunotherapy (C3i) in the First PanCanadian Strategic Forum, Cell & Gene Therapy Revolution. It’s an exciting time in the field of cell and gene therapy. The conference will highlight the most recent innovations in cell therapy, including cancer immunotherapies. BioCanRx’s vision is to cure patients and enhance the quality of life of those living with cancer. We support world-class research in the field of cancer immunotherapies by expediting the translation from bench to bedside of the most promising cancer biotherapeutics designed to save lives and enable a better quality of life. Through an innovative and collaborative funding process, BioCanRx is becoming a world-leader in the translation, manufacturing and implementation of innovative cancer biotherapeutics for the benefit of all cancer patients. This involves working with all sectors engaged in the fight against cancer: biotech, pharma, not-for-profits and patients.

BioCanRx supports a holistic approach to cancer research and clinical trials. As such, we were pleased to offer the pre-event workshop Working with Patients to Inform Early-phase Cancer Clinical Trial Design. BioCanRx network investigators highlighted how they will engage patients to inform early-phase clinical trial design of the first Made-in-Canada CAR-T therapy. They explored what patient-oriented research is, how it is used to inform and impact clinical trials currently, how BioCanRx intends to conduct patient-oriented research to inform cancer clinical trial design, and provide ways for patients to get involved.

BioCanRx looks forward to engaging with you throughout the conference as we explore gene and cell therapy – from discovery to the bedside.

Sincerely,

Stéphanie Michaud, PhD
President & Chief Executive Officer



The Centre for Commercialisation of Cancer Immunotherapy (C3i) would like to welcome all participants to CellCAN’s First PanCanadian Strategic Forum, Cell & Gene Therapy Revolution. We are on the cusp of a global revolution in medicine. Medical researchers and product developers are now poised to bring forward new gene, cell and tissue engineering therapies that hold great promise for profound and durable responses in patients exhibiting a diverse array of serious and costly conditions, many of which lack current treatments.

We, at C3i, are pleased to be a part of this partnership with CellCAN and BioCanRx as the objective of this innovative forum aligns with our mandate to accelerate discovery and commercialisation, thereby providing access to lifesaving breakthroughs in cancer immunotherapy.

Indeed, future continuous growth of cellular and gene therapies will require the collaboration amongst experts from various disciplines, including clinical medicine, manufacturing, commercialisation, regulatory and reimbursement, in an effort to maximize the success in bringing lifesaving therapies to patients.

We believe that you will find the topics and the program of this forum interesting, informative and inspirational. Our wish is for you to leave the conference enriched with ideas and plans for the future, with professional contacts and new friendships to support Canada’s leadership in this important medical revolution.

Sincerely,

François Bettez, B.Sc. M.Sc.
Chief Executive Officer



**Join Canada's
leading Stem Cell Researchers
at the annual Till & McCulloch Meetings**

To learn more about the 2017 scientific program and travel awards
keep an eye on Stem Cell Network's newsletter – CeLLlines.
To subscribe email: info@stemcellnetwork.ca



Connecting Canada's Stem Cell Research Community
tillandmcculloch.ca



SUMMIT FOR
CANCER
IMMUNOTHERAPY
JUNE 25 - 28, 2017
HILTON LAC-LEAMY | GATINEAU-OTTAWA



The 2nd Annual Summit for Cancer Immunotherapy

Early Bird Registration deadline:

April 19, 2017

www.cancersummit.ca

Centre pour la
commercialisation
du cancer
IMMUNOTHÉRAPIE



Center for
Commercialisation of
Cancer
IMMUNOTHERAPY

ACCELERATING MARKET ACCESS
TURNKEY SERVICES IN CANCER IMMUNOTHERAPY

Translate laboratory findings to the clinic	Outstanding Networking track record	Efficient Clinical trial research	A GMP facility for therapeutics production	Expertise in Regulatory processes	Expertise in immuno-therapy	Venture Capital Investment	A business oriented scientific-medical team
Introduire les nouveautés des laboratoires en clinique	Historique exceptionnel de réseautage	Unité de recherche clinique performante	Des installations GMP pour production thérapeutique	Expertise en processus réglementaire	Expertise en immuno-thérapie	Investissement en capital de risque	Une équipe médicale et scientifique dotée d'entrepreneurs

SERVICE CLÉ EN MAIN EN IMMUNOTHÉRAPIE DU CANCER
ACCÉLÉRER L'ACCÈS AU MARCHÉ

PROGRAM DAY 1 - MARCH 9, 2017

7:30 – 8:30	Registration Breakfast (sponsored by Stem Cell Network)	Exhibition Hall Montreal Room
8:30 – 8:40	Welcome from CellCAN – Regenerative Medicine and Cell Therapy Network Denis Claude Roy, CEO, CellCAN	Fortifications Room
8:40 – 9:00	Learning from the patients' perspectives Moderators: Michel Rochon, Scientific journalist Denis Claude Roy, CEO of CellCAN Patients: Jennifer Molson, Survivor of multiple sclerosis symptoms William Brock, Survivor of leukemia	Fortifications Room
Theme 1: Opportunities and challenges of recent innovations in cell and gene therapy		Fortifications Room
9:00 – 10:00	Innovation in cancer therapies: CAR-T, game changer in cancer treatment? Overview of the CAR-T revolution Jerome Ritz, Executive Director, Connell O'Reilly Cell Manipulation at the Dana Farber Cancer Institute The TAC receptor: Taking a new CAR for a spin Jonathan Bramson, Director, Fraunhofer Project Centre for Biomedical Engineering and Advanced Manufacturing	
10:00 – 10:30	Health break and exhibitors visit (sponsored by the Canadian Stem Cell Foundation)	
10:30 – 11:30	Innovation in viral and gene therapies Oncolytic virus to promote anticancer activity John Bell, Senior Scientist, Centre for Innovative Cancer Research, Ottawa Hospital Research Institute CRISPR/Cas9 may be used to treat hereditary diseases Jacques Tremblay, Professor in the Department of Molecular Medicine, Laval University	
11:30 – 13:00	Lunch, networking and exhibitors visit (sponsored by BioCanRx)	Montreal Room
Theme 2: Preparing the cell and gene therapy revolution		Fortifications Room
13:00 – 13:40	Dr. Janet Rossant presents the Council of Canadian Academies (CCA) latest workshop report on the opportunities and challenges for regenerative medicine in Canada Dr. Janet Rossant, President and Scientific Director of the Gairdner Foundation and Chair of the steering committee of the CCA workshop on regenerative medicine	

PROGRAM DAY 1 - MARCH 9, 2017

13:40 – 14:10	Key enablers and barriers for cell and gene therapy translation in Canada Joanne Castonguay, Research director, Institute for Research on Public Policy (IRPP)		
14:10 – 15:10	Panel on advancing cell therapy through national strategies and initiatives: international examples The California experience (CIRM) Geoffrey Lomax, Senior Officer, CIRM Strategic Infrastructure How Britain makes it work (Catapult) Dominic Bowers, Head of Clinical Operations & Development, Catapult Fast-tracking strategies in Japan (Jetro) Tyson Garbe, Assistant Director, Trade and Investment, JETRO Toronto		
15:10 – 15:30	Health break and exhibitors visit (sponsored by CCRM)		
15:30 – 16:30	Parallel workshops: Addressing key elements to engage in the cell and gene therapy revolution		
	Saint-Antoine Room	Ville-Marie A Room	Ville-Marie B Room
	Strategically planning for manufacturing changes between early and late clinical trials Moderator: Patrick Bedford, Manager, Clinical Translation & Regulatory Affairs, CCRM Nadine Kolas, Senior Policy Analyst, Health Canada Sowmya Viswanathan, CellCAN Manufacturing Platform Leader, Assistant Professor, Institute of Biomaterials and Biomedical Engineering, University of Toronto, Affiliate Scientist, Krembil Research Institute, University Health Network	Quality gaps in funding requests for translational projects Phil Welford, Executive Director, Stem Cell Network	Ethics and “Cellular Genomics”? Bartha Knoppers, Director of the Centre of Genomics and Policy at the Faculty of Medicine, McGill University
16:30 – 16:45	Report on parallel workshops Wrap-up of the day		Fortifications Room
16:45 – 17:00	Denis Claude Roy is proud to introduce... ISCT ANNOUNCEMENT, Queenie Jang, Executive Director, International Society for Cell Therapy Denis Coderre, Montreal Mayor		
17:00 – 18:30	Cocktail (sponsored by C3i)		Exhibition Hall



To learn more about our speakers, visit www.cellcan.com/forum2017/speakers.

PROGRAM DAY 2 - MARCH 10, 2017

7:30 – 8:30	Registration Breakfast	Exhibition Hall Montreal Room						
8:30 – 8:35	Introduction to day 2 activities Michel Rochon, Scientific journalist	Fortifications Room						
Theme 3: Manufacturing: what we have learned and what the future holds		Fortifications Room						
Moderators: Michel Rochon, Scientific journalist Armand Keating, Director, Cell Therapy Program, University Health Network								
8:35 – 9:35	Manufacturing: Foundation of the cell and gene therapy revolution Manufacturing of CAR-Ts Isabelle Rivière, Director, Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center Clarifying the meaning of GMP, GLP, QA, QC, etc. Adrian Gee, Director, Clinical Applications Lab, Baylor College of Medicine							
9:35 – 10:35	Panel on manufacturing to deliver novel therapies to patients Manufacturing in an academic setting Jerome Ritz, Executive Director, Connell O'Reilly Cell Manipulation, Dana Farber Cancer Institute Translating academia to industry Philippe Hénon, President and Scientific Director, CellProthera							
10:35 – 11:00	Health break and exhibitors visit (sponsored by Novartis)							
11:00 – 11:50	Parallel workshops: Reflection on cell and gene manufacturing enhancing approaches							
<table><tr><th>Saint-Antoine Room</th><th>Ville-Marie A Room</th><th>Ville-Marie B Room</th></tr><tr><td>Sharing vision for manufacturing autologous CAR-T cells Raelyn Rosa, MSc Design Engineer, Octane Biotech Paul Bowles, Development Scientist, GE Cell Therapy Technologies</td><td>Innovation to address unmet needs James Piret, University of British Columbia Professor and CellCAN Bioengineering Leader</td><td>CRISPR From bacteria to cell therapy David Guay, Research Director, Feldan Therapeutics</td></tr></table>			Saint-Antoine Room	Ville-Marie A Room	Ville-Marie B Room	Sharing vision for manufacturing autologous CAR-T cells Raelyn Rosa, MSc Design Engineer, Octane Biotech Paul Bowles, Development Scientist, GE Cell Therapy Technologies	Innovation to address unmet needs James Piret, University of British Columbia Professor and CellCAN Bioengineering Leader	CRISPR From bacteria to cell therapy David Guay, Research Director, Feldan Therapeutics
Saint-Antoine Room	Ville-Marie A Room	Ville-Marie B Room						
Sharing vision for manufacturing autologous CAR-T cells Raelyn Rosa, MSc Design Engineer, Octane Biotech Paul Bowles, Development Scientist, GE Cell Therapy Technologies	Innovation to address unmet needs James Piret, University of British Columbia Professor and CellCAN Bioengineering Leader	CRISPR From bacteria to cell therapy David Guay, Research Director, Feldan Therapeutics						
11:50 – 12:10	Report on parallel workshops	Fortifications Room						
12:10 – 13:30	Lunch, networking and exhibitors visit (sponsored by C3i)	Montreal Room						

PROGRAM DAY 2 - MARCH 10, 2017

Theme 4: Making Canada a central hub for commercializing cell and gene therapy		Fortifications Room
Moderators: Michel Rochon, Scientific journalist Lambert Busque, Chief Medical Officer, Center for Commercialisation of Cancer Immunotherapy (C3i)		
13:30 – 14:30	Successful cell and gene therapy business models Getting a start-up going Jonathan Bramson, Director, Fraunhofer Project Centre for Biomedical Engineering and Advanced Manufacturing Building a business case for venture capitals Michael May, CEO, Center for Commercialisation of Regenerative Medicine (CCRM) Center for Commercialisation of Cancer Immunotherapy business model Lambert Busque, Chief Medical Officer, C3i	
14:30 – 15:00	Making cell and gene therapy happen in Canada... who will pay and how much Cost effectiveness analysis Tania Bubela, Professor, School of Public Health, University of Alberta	
15:00 – 15:30	Health break and exhibitors visit	
15:30 – 16:00	Panel on reimbursement issues of cell and gene therapy Canadian perspective on reimbursement Maureen Trudeau, Chair for the Expert Review Committee of the pan Canadian Oncology Drug Review (pCODR) Integration of innovation in Quebec: INESSS perspective Michèle de Guise, Director, Direction des services de santé et de l'évaluation des technologies, Institut national d'excellence en santé et en services sociaux (INESSS)	Fortifications Room
16:00 – 16:30	Vision for Canada from the key structuring networks Closing remarks and next steps Denis Claude Roy, CEO, CellCAN	Fortifications Room



To learn more about our speakers, visit www.cellcan.com/forum2017/speakers.



Stem Cell Network
Réseau de cellules souches

Stay In Touch & Up To Speed On:

- ✓ Travel awards for the 2017 Till & McCulloch Meeting;
- ✓ SCN training opportunities;
- ✓ International travel awards;
- ✓ Travel bursaries; and
- ✓ SCN's lab exchange program.

Subscribe to SCN's monthly newsletter, **CELLines** by contacting: stemcellnetwork.ca

dalacombe@stemcellnetwork.ca

@StemCellNetwork

@CanadianStemCellNetwork

The Stem Cell Network has a mission to *act as a catalyst for enabling the translation of stem cell research into clinical applications, commercial products and public policy*. In just over 15 years SCN has forged a national community that has transformed stem cell research in Canada and has pushed the boundaries of what was a basic research area towards translational outcomes for the clinic and marketplace. By the end of 2016, SCN provided over \$90 million for innovative translational research. This strategic funding has benefitted approximately 160 world-class research groups and more than 2,500 trainees from across Canada.

stemcellnetwork.ca

Supporting Your Business from Concept to Market

CCRM's consulting, contract development and manufacturing services can:

BUILD your company	ADVANCE your research	BRIDGE the gap	DELIVER your product
Business, regulatory and IP team with commercialization and technology expertise	Cell reprogramming and engineering, technology translation and protocol development	Pre-clinical to commercially-ready cell and gene therapy process optimization and scale-up	GMP cell and gene therapy manufacturing, coming late 2017



Contact us for more information:

416.978.3751 | www.ccrm.ca | cdmo@ccrm.ca
MaRS Centre, West Tower
661 University Avenue, Suite 1002
Toronto, Ontario, Canada M5G 1M1



Novartis Oncology

Novartis Pharmaceuticals Canada Inc. is one of the country's leading healthcare companies committed to improving the health of Canadians.

We strive to discover and develop medicines that make a real difference.

There can be no delay. Patients are waiting.



CellCAN is also involved with the lay public

Discover our dissemination tools



Meet REGGIE


Discover the real potential of stem cells and their medical applications.

cellcan.com/meet_reggie




ILOVESTEMCELLS.CA | @CellCAN_Network

FLOOR PLANS



- 1 - CellCAN
- 2 - BioCanRx
- 3 - CCRM
- 4 - Roche
- 5 - BD
- 6 - BioSperix
- 7 - C3i



SPONSORS AND SUPPORTERS

THANKS TO OUR SPONSORS
AND OUR SUPPORTERS

GOLD / PARTNERS



SILVER



BRONZE



EXHIBITORS



SUPPORTERS



SPECIAL CONTRIBUTORS



JOIN CellCAN: CONTRIBUTE TO PUT KNOWLEDGE INTO ACTION!

Use **#cellcanforum** to join the online conversation



THANK YOU FOR YOUR PARTICIPATION

CellCAN
Regenerative Medicine and
Cell Therapy Network

5415 de L'Assomption Blvd
Pavillon Rachel-Tourigny, RT-2101
Montreal, Quebec, Canada H1T 2M4

www.cellcan.com
info@cellcan.com

